Immunization Schedule For Children And Adolescents Aged 18 Years Or Younger (Page 8 of 8) in pdf

For further guidance on the use of the vaccines mentioned below, see:

▪ Menactra

▪ For serogroup A, C, W, or Y: Administer or complete an

▪ If administered inadvertently to an adolescent aged 11

ɱ Children with anatomic or functional asplenia or

age- and formulation-appropriate series of MenHibrix,

through 18 years, the dose should be counted as the

HIV infection

Menactra, or Menveo.

adolescent Tdap booster.

▪ For serogroup B: Administer a 2-dose series of Bexsero,

• For other catch-up guidance, see Figure 2.

ʲ Children 24 months and older who have not received a

with doses at least 1 month apart, or a 3-dose series of

13. Human papillomavirus (HPV) vaccines. (Minimum age: 9

complete series. Administer 2 primary doses at least

Trumenba, with the second dose at least 1-2 months

years for 4vHPV [Gardasil] and 9vHPV [Gardasil 9])

8 weeks apart. If Menactra is administered to a child

after the first and the third dose at least 6 months after

Routine and catch-up vaccination:

with asplenia (including sickle cell disease) or HIV

the first. The two MenB vaccines are not interchangeable;

• Administer a 2-dose series of HPV vaccine on a schedule of

infection, do not administer Menactra until age 2

the same vaccine product must be used for all doses.

0, 6-12 months to all adolescents aged 11 or 12 years. The

years and at least 4 weeks after the completion of

For MenACWY booster doses among persons with high-risk

vaccination series can start at age 9 years.

all PCV13 doses.

conditions, refer to MMWR 2013;62(RR02):1-22, at

www.

• Administer HPV vaccine to all adolescents through age

ɱ Children with persistent complement component

cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm, MMWR

18 years who were not previously adequately vaccinated.

deficiency

June 20, 2014 / 63(24):527-530, at

The number of recommended doses is based on age at

ʲ Children 9 through 23 months. Administer 2 primary

pdf/wk/mm6324.pdf, and MMWR November 4, 2016 /

administration of the first dose.

doses at least 12 weeks apart.

65(43):1189-1194, at

volumes/65/wr/

• For persons initiating vaccination before age 15, the

ʲ Children 24 months and older who have not received

pdfs/mm6543a3.pdf.

recommended immunization schedule is 2 doses of HPV

a complete series. Administer 2 primary doses at

For other catch-up recommendations for these persons and

vaccine at 0, 6-12 months.

least 8 weeks apart.

complete information on use of meningococcal vaccines,

• For persons initiating vaccination at age 15 years or older,

ɱ All high-risk children

including guidance related to vaccination of persons at

the recommended immunization schedule is 3 doses of

ʲ If Menactra is to be administered to a child at high

increased risk of infection, see meningococcal MMWR

HPV vaccine at 0, 1–2, 6 months.

risk for meningococcal disease, it is recommended

publications, available at:

• A vaccine dose administered at a shorter interval should

that Menactra be given either before or at the same

recs/vacc-specific/mening.html.

be readministered at the recommended interval.

time as DTaP.

▪ In a 2-dose schedule of HPV vaccine, the minimum inter-

12. Tetanus and diphtheria toxoids and acellular pertussis

Meningococcal B vaccination of persons with high-risk

val is 5 months between the first and second dose. If the

(Tdap) vaccine. (Minimum age: 10 years for both Boostrix

conditions and other persons at increased risk of disease:

second dose is administered at a shorter interval, a third

and Adacel)

Children with anatomic or functional asplenia (including

dose should be administered a minimum of 12 weeks

Routine vaccination:

sickle cell disease) or children with persistent complement

after the second dose and a minimum of 5 months after

• Administer 1 dose of Tdap vaccine to all adolescents aged

component deficiency (includes persons with inherited or

the first dose.

11 through 12 years.

chronic deficiencies in C3, C5-9, properdin, factor D, factor

▪ In a 3-dose schedule of HPV vaccine, the minimum

• Tdap may be administered regardless of the interval since

H, or taking eculizumab [Soliris]):

intervals are 4 weeks between the first and second dose,

the last tetanus and diphtheria toxoid-containing vaccine.

▪ Bexsero or Trumenba

12 weeks between the second and third dose, and 5

• Administer 1 dose of Tdap vaccine to pregnant

ɱ Persons 10 years or older who have not received a com-

months between the first and third dose. If a vaccine

adolescents during each pregnancy (preferably during

plete series. Administer a 2-dose series of Bexsero, with

dose is administered at a shorter interval, it should be

the early part of gestational weeks 27 through 36),

doses at least 1 month apart, or a 3-dose series of

readministered after another minimum interval has been

regardless of time since prior Td or Tdap vaccination.

Trumenba, with the second dose at least 1–2 months

met since the most recent dose.

Catch-up vaccination:

after the first and the third dose at least 6 months

Special populations:

• Persons aged 7 years and older who are not fully

after the first. The two MenB vaccines are not inter-

• For children with history of sexual abuse or assault,

immunized with DTaP vaccine should receive Tdap

changeable; the same vaccine product must be used

administer HPV vaccine beginning at age 9 years.

vaccine as 1 dose (preferably the first) in the catch-up

for all doses.

• Immunocompromised persons*, including those with

series; if additional doses are needed, use Td vaccine. For

For children who travel to or reside in countries in which

human immunodeficiency virus (HIV) infection, should

children 7 through 10 years who receive a dose of Tdap

meningococcal disease is hyperendemic or epidemic,

receive a 3-dose series at 0, 1–2, and 6 months, regardless

as part of the catch-up series, an adolescent Tdap vaccine

including countries in the African meningitis belt or the

of age at vaccine initiation.

dose at age 11 through 12 years may be administered.

Hajj:

• Note: HPV vaccination is not recommended during

• Persons aged 11 through 18 years who have not received

▪ Administer an age-appropriate formulation and series of

pregnancy, although there is no evidence that the

Tdap vaccine should receive a dose, followed by tetanus

Menactra or Menveo for protection against serogroups A

vaccine poses harm. If a woman is found to be pregnant

and diphtheria toxoids (Td) booster doses every 10 years

and W meningococcal disease. Prior receipt of MenHibrix

after initiating the vaccination series, no intervention is

thereafter.

is not sufficient for children traveling to the meningitis

needed; the remaining vaccine doses should be delayed

• Inadvertent doses of DTaP vaccine:

belt or the Hajj because it does not contain serogroups

until after the pregnancy. Pregnancy testing is not

▪ If administered inadvertently to a child aged 7 through

A or W.

needed before HPV vaccination.

10 years, the dose may count as part of the catch-up

For children at risk during an outbreak attributable to a

*See MMWR December 16, 2016;65(49):1405-1408, available

series. This dose may count as the adolescent Tdap dose,

vaccine serogroup:

volumes/65/wr/pdfs/mm6549a5.pdf.

or the child may receive a Tdap booster dose at age 11

through 12 years.

CS270457-C

Immunization Schedule For Children And Adolescents Aged 18 Years Or Younger Page 8

Related Articles

Related forms

Related Categories